Status:

COMPLETED

Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Lead Sponsor:

German CLL Study Group

Conditions:

Chronic Lymphocytic Leukemia

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with t...

Detailed Description

OBJECTIVES: Primary * Compare the effect, in terms of event-free survival, of deferred versus immediate treatment with rituximab, fludarabine, and cyclophosphamide in patients with previously untrea...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Established diagnosis of B-cell chronic lymphocytic leukemia
  • First diagnosis within 12 months before inclusion in study
  • Previously untreated disease
  • Binet stage A disease (Rai stage 0, I, or II)
  • PATIENT CHARACTERISTICS:
  • Life expectancy \> 6 months
  • ECOG performance status 0-2
  • Willingness to accept contraception (if randomized to arm I) for the duration of therapy and 12 months thereafter
  • Negative serum pregnancy test
  • All parameters for risk stratification (lymphocyte doubling time, cytogenetics, unmutated IgVH, and serum thymidine kinase level \> 10) present
  • PRIOR CONCURRENT THERAPY:
  • No prior chemotherapy, radiotherapy, or antibody treatment
  • No other concurrent chemotherapy

Exclusion

    Key Trial Info

    Start Date :

    October 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2015

    Estimated Enrollment :

    825 Patients enrolled

    Trial Details

    Trial ID

    NCT00275054

    Start Date

    October 1 2005

    End Date

    June 1 2015

    Last Update

    May 23 2019

    Active Locations (91)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 23 (91 locations)

    1

    Universitaetsklinik fuer Innere Medizin I

    Vienna, Austria, A-1090

    2

    Centre Hospitalier Universitaire d'Amiens

    Amiens, France, 80054

    3

    Centre Hospitalier Regional et Universitaire d'Angers

    Angers, France, 49033

    4

    Centre Hospitalier Victor Dupouy

    Argenteuil, France, 95107

    Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | DecenTrialz